+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 50Years +
MALE
ID07788625

Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer

Led by The University of Hong Kong · Updated on 2026-08-26

60

Participants Needed

1

Research Sites

14 weeks

Total Duration

AI-Summary

What This Trial Is About

This research investigates the use of pelvis-only 18F-PSMA-1007 PET-CT imaging to detect clinically significant prostate cancers csPCa that are invisible on standard multiparametric MRI mpMRI. The study focuses on men aged 50 and older with localized, intermediate-risk prostate cancer, particularly those with MRI-invisible cancer areas identified only through biopsy. The goal is to see if PET-CT can guide targeted focal therapy, avoiding whole-gland treatment or active surveillance. This is a prospective, multi-center, single-arm Phase II trial conducted in Hong Kong. Participants undergo a PET-CT scan to detect PET-positive lesions that correspond to MRI-invisible biopsy sites. Those with matching PET-avid lesions receive focal therapy using one of three energy-based treatments targeted microwave ablation, high-intensity focused ultrasound, or irreversible electroporation. Treatments are carefully guided by organ-based tracking technology fused with real-time ultrasound, aiming to cover the PET-positive lesions plus any MRI-visible tumors with safety margins while protecting nearby critical structures. Treatments are delivered transperineally under anesthesia. During the study, participants have follow-ups at 3 and 6 months including PSA blood tests, symptom and quality-of-life questionnaires, and repeat imaging and biopsies to assess the presence of cancer in treated areas. The main measure is the absence of significant prostate cancer in treated zones at 6 months. Secondary outcomes include cancer recurrence outside treated areas, changes in PSA, functional effects, safety events, and quality of life. The study plans to enroll about 60 patients to achieve 45 treated cases, with a total duration of about 3 years.

CONDITIONS

Brief Title

¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer

Research Team

S

Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here